AntriaBio appoints Barry Sherman to board
This article was originally published in Scrip
AntriaBio, a biopharmaceutical company focused on developing treatments for diabetes and metabolic diseases, has named Dr Barry Sherman to its board of directors. Notably, Dr Sherman was the first chief medical officer of Genentech in the mid-1990s following his role directing Genentech's clinical research and medical affairs teams. He has also served as president and CEO of StemPar Sciences, president and CEO of Anergen Inc, a founder of Pain Therapeutics, and the executive vice-president and co-founder of BiPar Sciences.